{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:29:48Z","timestamp":1792459788249,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,8,8]],"date-time":"2013-08-08T00:00:00Z","timestamp":1375920000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1007\/s00277-013-1865-3","type":"journal-article","created":{"date-parts":[[2013,8,7]],"date-time":"2013-08-07T09:35:04Z","timestamp":1375868104000},"page":"249-253","source":"Crossref","is-referenced-by-count":37,"title":["Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma)"],"prefix":"10.1007","volume":"93","author":[{"given":"Barbara","family":"Kiesewetter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius E.","family":"Mayerhoefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius","family":"Lukas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph C.","family":"Zielinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonhard","family":"M\u00fcllauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Raderer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,8,8]]},"reference":[{"key":"1865_CR1","first-page":"158","volume-title":"WHO classification of tumours of the haematopoietic and lymphoid tissues","author":"ES Jaffe","year":"2008","unstructured":"Jaffe ES, Harris NL, Stein H, Campo E et al (2008) Introduction and overview of the classification of the lymphoid neoplasms. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA (eds) WHO classification of tumours of the haematopoietic and lymphoid tissues. IARC, Lyon, pp 158\u2013166, 2008"},{"key":"1865_CR2","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1200\/JCO.2006.06.0723","volume":"24","author":"M Raderer","year":"2006","unstructured":"Raderer M, W\u00f6hrer S, Streubel B et al (2006) Assessment of disease dissemination in gastric compared with extragastric mucosa-associated lymphoid tissue lymphoma using extensive staging: a single-centre experience. J Clin Oncol 24:3136\u201341","journal-title":"J Clin Oncol"},{"key":"1865_CR3","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/blood.V95.3.802.003k19_802_806","volume":"95","author":"C Thieblemont","year":"2000","unstructured":"Thieblemont C, Berger F, Dumontet C et al (2000) Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood 95:802\u20136","journal-title":"Blood"},{"key":"1865_CR4","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1158\/1078-0432.CCR-04-2282","volume":"11","author":"M Raderer","year":"2005","unstructured":"Raderer M, Streubel B, Woehrer S et al (2005) High relapse rate in patients with MALT lymphoma warrants lifelong follow-up. Clin Cancer Res 11:3349\u201352","journal-title":"Clin Cancer Res"},{"key":"1865_CR5","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.1200\/JCO.2003.06.085","volume":"21","author":"RW Tsang","year":"2003","unstructured":"Tsang RW, Gospodarowicz MK, Pintilie M et al (2003) Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol 21:4157\u201364","journal-title":"J Clin Oncol"},{"key":"1865_CR6","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ijrobp.2009.04.018","volume":"77","author":"SH Son","year":"2010","unstructured":"Son SH, Choi BO, Kim GW et al (2010) Primary radiation therapy in patients with localized orbital marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). Int J Radiat Oncol Biol Phys 77:86\u201391","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1865_CR7","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.2011.40.6272","volume":"31","author":"E Zucca","year":"2013","unstructured":"Zucca E, Conconi A, Laszlo D et al (2013) Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis if the IELSG-19 randomized study. J Clin Oncol 31:565\u201372","journal-title":"J Clin Oncol."},{"key":"1865_CR8","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.ophtha.2006.01.057","volume":"113","author":"GJ Ben Simon","year":"2006","unstructured":"Ben Simon GJ, Cheung N, McKelvie P et al (2006) Oral cholrambucil for extranodal, marginal zone, B-cell lymphoma if mucosa-associated lymphoid tissue of the orbit. Ophthalmology 113:1209\u201313","journal-title":"Ophthalmology"},{"key":"1865_CR9","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3324\/haematol.2012.072587","volume":"98","author":"M Troch","year":"2013","unstructured":"Troch M, Kiesewetter B, Willenbacher W et al (2013) Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentoese Tumortherapie. Haematologica 98:264\u20138","journal-title":"Haematologica"},{"key":"1865_CR10","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1200\/JCO.2002.05.117","volume":"20","author":"G J\u00e4ger","year":"2002","unstructured":"J\u00e4ger G, Neumeister P, Brezinschek R et al (2002) Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine. J Clin Oncol 20:3872\u20137","journal-title":"J Clin Oncol"},{"key":"1865_CR11","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1002\/cncr.24605","volume":"115","author":"A Salar","year":"2009","unstructured":"Salar A, Domingo-Domenech E, Estany C et al (2009) Combination therapy with rituximab and intravenous or oral fudarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mcuosa-associated lymphoid tissue type. Cancer 115:5210\u20137","journal-title":"Cancer"},{"key":"1865_CR12","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/j.1365-2141.2009.07677.x","volume":"145","author":"JR Brown","year":"2009","unstructured":"Brown JR, Friedberg JW, Feng Y et al (2009) A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. Br J Haematol 145:741\u20138","journal-title":"Br J Haematol"},{"key":"1865_CR13","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1159\/000098555","volume":"70","author":"M Raderer","year":"2006","unstructured":"Raderer M, Wohrer S, Streubel B et al (2006) Activity of rituximab plus cyclophosphamide, doxorubicin\/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma. Oncology 70:411\u20137","journal-title":"Oncology"},{"key":"1865_CR14","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1080\/10428190701636476","volume":"48","author":"D Ennishi","year":"2007","unstructured":"Ennishi D, Yokoyama M, Mishima Y et al (2007) Rituximab plus CHOP as an initial chemotherapy for patients with disseminated MALT lymphoma. Leuk Lymphoma 48:2241\u20133","journal-title":"Leuk Lymphoma"},{"key":"1865_CR15","doi-asserted-by":"crossref","unstructured":"Rummel MJ, Niederle N, Maschmeyer G et al (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381(9873):1203\u201310","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"1865_CR16","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1054\/bjoc.2000.1308","volume":"83","author":"M Raderer","year":"2000","unstructured":"Raderer M, Vorbeck F, Formanek M et al (2000) Importance of extensive staging in patients with mucosa-associated lymphoid tissue (MALT)-type lymphoma. Br J Cancer 83:454\u20137","journal-title":"Br J Cancer"},{"key":"1865_CR17","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u201347","journal-title":"Eur J Cancer"},{"key":"1865_CR18","doi-asserted-by":"crossref","unstructured":"Salar A, Domingo-Domenech E, Panizo C et al (2012) Final results of a multicenter phase II trial with Bendamustine and Rituximabas first line treatment for patients with MALT lymphoma (MALT-2008-01). ASH Annual Meeting Abstracts 2012 (abstr 3691)","DOI":"10.1182\/blood.V120.21.3691.3691"},{"key":"1865_CR19","doi-asserted-by":"crossref","unstructured":"Cheson BD. New response criteria for lymphomas in clinical trials (2008) Ann Oncol 19 (suppl4), iv35-iv38","DOI":"10.1093\/annonc\/mdn191"},{"key":"1865_CR20","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1385\/MO:22:1:057","volume":"22","author":"A Avil\u00e9s","year":"2005","unstructured":"Avil\u00e9s A, Nambo MJ, Neri N et al (2005) Mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach: results of a controlled clinical trial. Med Oncol 22:57\u201362","journal-title":"Med Oncol"},{"key":"1865_CR21","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1093\/annonc\/mdl126","volume":"17","author":"G J\u00e4ger","year":"2006","unstructured":"J\u00e4ger G, Neumeister P, Quehenberger F et al (2006) Prolonged clinical remission in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type treated with cladribine: 6-year follow-up of a phase II trial. Ann Oncol 17:1722\u20133","journal-title":"Ann Oncol"},{"key":"1865_CR22","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/gut.2010.224949","volume":"60","author":"A Ruskon\u00e9-Fourmestraux","year":"2011","unstructured":"Ruskon\u00e9-Fourmestraux A, Fischbach W, Aleman BM et al (2011) EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut 60:747\u201358","journal-title":"Gut"},{"issue":"Suppl 5","key":"1865_CR23","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/annonc\/mdq182","volume":"21","author":"E Zucca","year":"2010","unstructured":"Zucca E, Dreyling M, Guidelines Working Group ESMO (2010) Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):175\u20136","journal-title":"Ann Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-013-1865-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-013-1865-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-013-1865-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T15:04:25Z","timestamp":1596294265000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-013-1865-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,8]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["1865"],"URL":"https:\/\/doi.org\/10.1007\/s00277-013-1865-3","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,8]]}}}